Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pretax income is the income that a company earns before paying income taxes. Petros Pharmaceuticals's pretax income for the
three
months ended in Jun. 2026 was $-0.96 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Jun. 2026 was $-3.20 Mil.
Petros Pharmaceuticals's pretax margin was %.
During the past 7 years, Petros Pharmaceuticals's highest Pretax Margin was -115.06%. The lowest was -334.41%. And the median was -212.86%.
During the past 7 years, Petros Pharmaceuticals's highest Pretax Margin was -115.06%. The lowest was -334.41%. And the median was -212.86%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals Pre-Tax Income Related Terms
Petros Pharmaceuticals Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Petros Pharmaceuticals's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PTPI vs GRPS, KOAN, OWPC: Pre-Tax Income Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Petros Pharmaceuticals Pre-Tax Income vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Petros Pharmaceuticals's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Petros Pharmaceuticals (PTPI) has a Pre-Tax Income of $-3.20 Mil as of Jun. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Petros Pharmaceuticals and its competitors.
Is Petros Pharmaceuticals' Pre-Tax Income too high?
Petros Pharmaceuticals' current Pre-Tax Income is $-3.20 Mil.
How does Petros Pharmaceuticals' Pre-Tax Income compare to GRPS and KOAN?
Petros Pharmaceuticals' Pre-Tax Income of $-3.20 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Petros Pharmaceuticals and its competitors. Petros Pharmaceuticals's current Pre-Tax Income is $-3.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Pre-Tax Income of $-3.20 Mil. The current Pre-Tax Income is $-3.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Pre-Tax Income is $-3.20 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PTPI has been successfully added to your 
